MedTrace Logo

Phase II Clinical Trial of OCH-NCNP1

NCT04211740 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-11-09

No results posted yet for this study

Summary

This study is designed to assess the efficacy and safety of OCH-NCNP1 compared to placebo in subjects diagnosed with relapsing remitting multiple sclerosis (RRMS) and secondary progressive mltiple sclerosis (SPMS) .

Conditions

  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis, Secondary Progressive

Interventions

DRUG

OCH-NCNP1

OCH-NCNP1 3mg is supplied as granules and take orally once a week.

DRUG

Placebo

Placebo is supplied as granules and take orally once a week.

Sponsors & Collaborators

  • National Center of Neurology and Psychiatry, Japan

    lead OTHER

Principal Investigators

  • Tomoko Okamoto, MD · National Center of Neurology and Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-06
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04211740 on ClinicalTrials.gov